BELINOSTAT - INJECTION
PHONETIC PRONUNCIATION: (be-LIN-oh-stat)
COMMON BRAND NAME(S): Beleodaq
GENERIC NAME(S): belinostat
Uses
USES: Belinostat is used to treat a certain type of cancer: peripheral T-cell lymphoma (PTCL). It is used when other drugs do not work or when the cancer comes back after treatment. Belinostat works by slowing or stopping the growth of cancer cells.
How to use BELINOSTAT - INJECTION
HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start using belinostat and each time you get a refill. If you have any questions, ask your doctor or pharmacist. This medication is given by a health care professional in a clinic or hospital. It is injected into a vein as directed by your doctor, usually once a day on days 1 through 5 of a 21-day treatment cycle. The injection is given slowly, usually over 30 minutes. Tell your doctor or nurse right away if you notice redness, pain, or swelling during your injection. If you have side effects during the injection, your infusion may be given over a longer time, changed, or temporarily stopped. The dosage is based on your medical condition, body size, laboratory test results, and response to treatment. To get the most benefit from this medication, do not miss any doses. To help you remember, mark the days when you are scheduled to receive treatment on your calendar.
Side Effects
Precautions
Interactions
Overdose
Images
Reviews
Faq for BELINOSTAT - INJECTION
Belinostat injection is used to treat a type of cancer called peripheral T-cell lymphoma (PTCL) in patients who have not responded to other treatments.
Belinostat is a histone deacetylase (HDAC) inhibitor, which means it blocks enzymes that help cancer cells grow and divide. This helps to slow down or stop the growth of cancer cells.
Belinostat is administered as an intravenous (IV) infusion, which means it is injected directly into a vein over a period of time.
Common side effects of Belinostat injection include fatigue, nausea, vomiting, diarrhea, anemia, and loss of appetite. It can also cause low blood platelet counts and low white blood cell counts.
Yes, Belinostat injection is FDA-approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).
The duration of treatment with Belinostat injection can vary depending on the individual and their response to the medication. It is usually given in cycles, with rest periods in between.
Yes, Belinostat can be used in combination with other cancer treatments, such as chemotherapy, radiation therapy, or targeted therapy, based on the patient's specific condition and the treating doctor's recommendation.
Belinostat injection may cause severe or life-threatening side effects, such as infections, liver toxicity, and lung problems. It is important to closely monitor patients receiving Belinostat and take necessary precautions.
Belinostat may cause harm to an unborn baby, so it is not recommended to use during pregnancy. It is also not known whether it passes into breast milk, so breastfeeding is not advised while receiving Belinostat.
Disclaimer
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
No Reviews Yet